Vertex completes $10.0 billion acquisition of Crinetics Pharmaceuticals
The merger closed September 1, 2026, converting Crinetics shares into $85.00 per share in cash and installing new leadership at the surviving subsidiary.
SEC filing
Latest
7 stories
Tuesday, September 1
Vertex names Jonathan Poole as next CFO, effective January 2027
Charles Wagner will hand off the CFO role but stay on as chief operating officer, per an 8-K filed with the SEC.
SEC filing
Monday, August 31
Vertex collaborator registers exploratory trial of Journavx for ankle replacement pain
Friday, August 28
Vertex registers Phase 1 drug interaction study for VX-407 with oral contraceptives
Monday, August 3
Vertex raises 2026 revenue guidance, sets povetacicept PDUFA date and Crinetics deal timing
Vertex lifted its full-year revenue outlook and disclosed a November 30 FDA decision date for povetacicept in IgA nephropathy while confirming plans to close its Crinetics acquisition in the third quarter.
SEC filing
Monday, July 13
VCU registers END-EXT natural history study for myotonic dystrophy type 1; Dyne, Vertex collaborate
Friday, July 10
Crinetics discloses non-compete deals with executives tied to Vertex merger
The agreements, signed July 6, 2026, restrict Crinetics' CEO, CFO, CSO, and chief commercial officer from competing for a year after the deal closes.
SEC filing